Research Update on Dementia and Alzheimer ’ s Disease
Clioquinol, a copper chelator that may prevent copper and zinc from binding the beta amyloid, was recently found to have beneficial effects on slowing deterioration in AD and suggest potentially new avenues for clinical research.
Abstract
Copper and Alzheimer’s Disease (AD) There is accumulating evidence suggesting an association between copper levels in the blood and deficits of AD. In a recent report by Squitti and coauthors (Neurology, 2009; 72: 50-55), free copper levels as measured by ceruloplasmin were correlated with lower functional levels. Clioquinol, a copper chelator that may prevent copper and zinc from binding the beta amyloid, was recently found to have beneficial effects on slowing deterioration in AD. These findings suggest potentially new avenues for clinical research.